Summary
A diverse variety of medical or lifestyle conditions lead to a progressive loss of muscle force by functionally impairing myofibril contractility and causing ultimately myofibril loss. Major underlying risk factors of chronic muscle force loss are ageing, inactive lifestyles, and unbalanced nutrition. Together, these factors are predicted to lead to an endemic incidence of muscle weakness both in the developed countries. Clinical research on the mechanisms involved requires a multidisciplinary approach covering aspects of ageing, metabolism, and on the humoral cross-talk of muscle with other key organs including heart, liver, kidney, and lung. To achieve this, six European groups with complementary expertise in inter-organ-cross-talk during stress-induced secondary myopathies will team-up with three leading teams in the U.S. with expertise in myopathy animal models, myofilament proteins and translation of muscle research into therapeutic interventions, and with one team from South Africa with cutting-edge expertise in the regulation of regenerative capacities in muscle.
Importantly, five SMEs will participate in this RISE network that provide expertise in early muscle disease detection, monitoring, and the developing preventive strategies: Their knowledge on muscle disease detection at early stages and their monitoring during interventions will promote translational innovation. To implement innovation and our joint research program, both early stage and advanced researchers will be seconded from the academic nine teams to these five SMEs and vice versa. Thereby, this RISE scheme will establish a long-term collaborative University-SME driven translational innovative research program innovation in our interdisciplinary field of growing socioeconomic medical importance.
Importantly, five SMEs will participate in this RISE network that provide expertise in early muscle disease detection, monitoring, and the developing preventive strategies: Their knowledge on muscle disease detection at early stages and their monitoring during interventions will promote translational innovation. To implement innovation and our joint research program, both early stage and advanced researchers will be seconded from the academic nine teams to these five SMEs and vice versa. Thereby, this RISE scheme will establish a long-term collaborative University-SME driven translational innovative research program innovation in our interdisciplinary field of growing socioeconomic medical importance.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/645648 |
Start date: | 01-03-2016 |
End date: | 29-02-2020 |
Total budget - Public funding: | 1 606 500,00 Euro - 1 458 000,00 Euro |
Cordis data
Original description
A diverse variety of medical or lifestyle conditions lead to a progressive loss of muscle force by functionally impairing myofibril contractility and causing ultimately myofibril loss. Major underlying risk factors of chronic muscle force loss are ageing, inactive lifestyles, and unbalanced nutrition. Together, these factors are predicted to lead to an endemic incidence of muscle weakness both in the developed countries. Clinical research on the mechanisms involved requires a multidisciplinary approach covering aspects of ageing, metabolism, and on the humoral cross-talk of muscle with other key organs including heart, liver, kidney, and lung. To achieve this, six European groups with complementary expertise in inter-organ-cross-talk during stress-induced secondary myopathies will team-up with three leading teams in the U.S. with expertise in myopathy animal models, myofilament proteins and translation of muscle research into therapeutic interventions, and with one team from South Africa with cutting-edge expertise in the regulation of regenerative capacities in muscle.Importantly, five SMEs will participate in this RISE network that provide expertise in early muscle disease detection, monitoring, and the developing preventive strategies: Their knowledge on muscle disease detection at early stages and their monitoring during interventions will promote translational innovation. To implement innovation and our joint research program, both early stage and advanced researchers will be seconded from the academic nine teams to these five SMEs and vice versa. Thereby, this RISE scheme will establish a long-term collaborative University-SME driven translational innovative research program innovation in our interdisciplinary field of growing socioeconomic medical importance.
Status
CLOSEDCall topic
MSCA-RISE-2014Update Date
28-04-2024
Images
No images available.
Geographical location(s)